Sanofi’s Teizeild Wins European Commission Approval for Type 1 Diabetes Treatment

French pharmaceutical giant Sanofi has received approval from the European Commission for its groundbreaking therapy Teizeild (teplizumab) to delay the progression of stage 2 to stage 3 type 1 diabetes (T1D) in patients aged eight years and older. This decision follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use and marks the first time a disease‑modifying T1D therapy has been authorized in the European Union, representing a significant milestone in autoimmune diabetes care. The approval is grounded in data from the TN‑10 Phase 2 clinical study, which showed that Teizeild delayed the onset of stage 3 T1D by a median of two years compared to placebo in both adults and children with stage 2 disease. In the study, a greater proportion of patients treated with Teizeild remained in stage 2 T1D versus those receiving placebo. Teizeild’s safety profile was consistent with previous trials, with common events including transient lymphopenia and rash. Teizeild, known outside the EU as Tzield, is already approved in multiple countries including the United States, UK, China, Canada, Israel, Saudi Arabia, UAE, and Kuwait for the same indication. Sanofi said it will continue evaluating further regulatory opportunities while supporting access across Europe. #Sanofi #Teizeild #Type1Diabetes #EUMedicalApproval #SlimScan #GrowthStocks #CANSLIM